🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

ConforMIS (CFMS) Gets FDA Approval For ITotal Hip System

Published 06/25/2017, 09:20 PM
Updated 07/09/2023, 06:31 AM
LMNX
-
AXDX
-
INGN
-
CFMS
-

Medical technology company, ConforMIS, Inc. (NASDAQ:CFMS) recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.

The ConforMIS iTotal Hip system features proprietary iFit image-to-implant technology. The system utilizes the company’s patient-specific technology and single-use 3D printed instruments. The iTotal Hip system is expected to be launched in 2019.

Per management, standard hip replacement surgery involves challenges and risk of dislocation and discrepancies in leg length. The ConforMIS iTotal Hip system is designed to overcome these challenges and risks and improve outcomes as this is designed to match a patient’s anatomy. This product will expand the company’s product portfolio to address a broader orthopedic market.

We are bullish on the ConforMIS’ focus on the rapidly growing hip replacement market. Approximately 400,000 hip replacements were performed in the domestic market in 2016.

According to Data Bridge Market Research, the global hip replacement implants market is expected to reach a worth of $7.1 billion by 2024 at a CAGR of 3.6% during the 2017 to 2024 period.So, the company clearly has bountiful opportunities in this niche market.

According to a study of HealthDay over 10 years from 2000 to 2010, the number of hip replacements has sky rocketed from 138,700 in 2000 to 310,800 in 2010. So the company, in line with its peers Inogen, Inc. (NASDAQ:INGN) , Luminex Corporation (NASDAQ:LMNX) and Accelerate Diagnostics, Inc. (NASDAQ:AXDX) , are taking strategic steps to gain traction in the untapped market.

ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to suit each patient’s unique anatomy.

The Best & Worst of Zacks

Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>



Luminex Corporation (LMNX): Free Stock Analysis Report

Inogen, Inc (INGN): Free Stock Analysis Report

Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report

ConforMIS, Inc. (CFMS): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.